Patent intelligence · US
US 12221610
RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
Patent details — US 12221610
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 11, 2025
- Expiration
- Feb 6, 2045
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/7088, A61P, A61P35/00
Quick answer
US 12221610 (RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use) is held by Arrowhead Pharmaceuticals, Inc.. Status: granted. Granted Feb 11, 2025. Expires Feb 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/7088, A61P, A61P35/00
More from Arrowhead Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12378558
RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use
granted -
US 12365897
RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
granted -
US 12365899
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
granted -
US 12188017
Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
granted -
US 12173086
Alpha-v beta-6 integrin ligands and uses thereof
granted -
US 12116573
Targeting ligands for therapeutic compounds
granted -
US 12110492
RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use
granted
Related coverage
Frequently asked questions
What is US patent 12221610?
US 12221610 (RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use) is held by Arrowhead Pharmaceuticals, Inc.. Status: granted. Granted Feb 11, 2025. Expires Feb 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12221610?
Arrowhead Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 126 pharmaceutical patents for this assignee.
When does US 12221610 expire?
Our index shows an expiration date of Feb 6, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.